Evidence map›Paper›PMID 37726448›Full record

ArticleCommunications biology2023

Deep learning driven de novo drug design based on gastric proton pump structures.

Kazuhiro Abe, Mami Ozako, Miki Inukai, Yoe Matsuyuki, Shinnosuke Kitayama, Chisato Kanai, Chiaki Nagai, Chai C Gopalasingam, Christoph Gerle, Hideki Shigematsu and 3 more

Abstract read
In one paragraph

Article in Communications biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Molecular Structure of the NaInternational journal of molecular sciences · 2024
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kazuhiro AbeCellular and Structural Physiology Institute, Nagoya University, Nagoya, Aichi, 464-8601, Japan. kabe@cespi.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0003-2681-5921
Mami OzakoGraduate School of Pharmaceutical Sciences, Nagoya University, Nagoya, Aichi, 464-8601, Japan.
Miki InukaiGraduate School of Pharmaceutical Sciences, Nagoya University, Nagoya, Aichi, 464-8601, Japan.
Yoe MatsuyukiGraduate School of Pharmaceutical Sciences, Nagoya University, Nagoya, Aichi, 464-8601, Japan.
Shinnosuke KitayamaGraduate School of Pharmaceutical Sciences, Nagoya University, Nagoya, Aichi, 464-8601, Japan.
Chisato KanaiINTAGE Healthcare, Inc., 3-5-7, Kawaramachi Chuo-ku, Osaka, 541-0048, Japan.
Chiaki NagaiGraduate School of Pharmaceutical Sciences, Nagoya University, Nagoya, Aichi, 464-8601, Japan.
Chai C GopalasingamRIKEN SPring-8 Center, Kouto, Sayo-gun, Hyogo, 679-5148, Japan.ORCID http://orcid.org/0000-0002-9014-9380
Christoph GerleRIKEN SPring-8 Center, Kouto, Sayo-gun, Hyogo, 679-5148, Japan.ORCID http://orcid.org/0000-0002-7265-2804
Hideki ShigematsuJapan Synchrotron Radiation Research Institute (JASRI), SPring-8, 1-1-1 Kouto, Sayo, Hyogo, 679-5148, Japan.ORCID http://orcid.org/0000-0003-3951-8651
Nariyoshi UmekuboGraduate School of Pharmaceutical Sciences, Nagoya University, Nagoya, Aichi, 464-8601, Japan.ORCID http://orcid.org/0000-0002-8242-2092
Satoshi YokoshimaGraduate School of Pharmaceutical Sciences, Nagoya University, Nagoya, Aichi, 464-8601, Japan. yokosima@ps.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0003-4036-0062
Atsushi YoshimoriInstitute for Theoretical Medicine, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012, Japan. yoshimori@itmol.com.ORCID http://orcid.org/0000-0003-3206-5143

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Existing drugs often suffer in their effectiveness due to detrimental side effects, low binding affinity or pharmacokinetic problems. This may be overcome by the development of distinct compounds. Here, we exploit the rich structural basis of drug-bound gastric proton pump to develop compounds with strong inhibitory potency, employing a combinatorial approach utilizing deep generative models for de novo drug design with organic synthesis and cryo-EM structural analysis. Candidate compounds that satisfy pharmacophores defined in the drug-bound proton pump structures, were designed in silico utilizing our deep generative models, a workflow termed Deep Quartet. Several candidates were synthesized and screened according to their inhibition potencies in vitro, and their binding poses were in turn identified by cryo-EM. Structures reaching up to 2.10 Å resolution allowed us to evaluate and re-design compound structures, heralding the most potent compound in this study, DQ-18 (N-methyl-4-((2-(benzyloxy)-5-chlorobenzyl)oxy)benzylamine), which shows a K

Indexed as

Deep LearningDrug DesignDrug DevelopmentPharmacophoreStomach

Identifiers

PMID37726448
PMCPMC10509173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.